PL3898637T3 - Pochodne rapamycyny - Google Patents

Pochodne rapamycyny

Info

Publication number
PL3898637T3
PL3898637T3 PL19836546.2T PL19836546T PL3898637T3 PL 3898637 T3 PL3898637 T3 PL 3898637T3 PL 19836546 T PL19836546 T PL 19836546T PL 3898637 T3 PL3898637 T3 PL 3898637T3
Authority
PL
Poland
Prior art keywords
rapamicin
derivatives
rapamicin derivatives
Prior art date
Application number
PL19836546.2T
Other languages
English (en)
Inventor
Simone BONAZZI
Michael Connolly
David J. Glass
Manuel Mihalic
Andrew W. Patterson
Silvio Roggo
Tea Shavlakadze
Patrik ZUEGER
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3898637T3 publication Critical patent/PL3898637T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19836546.2T 2018-12-18 2019-12-17 Pochodne rapamycyny PL3898637T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862781242P 2018-12-18 2018-12-18
PCT/IB2019/060957 WO2020128861A1 (en) 2018-12-18 2019-12-17 Rapamycin derivatives

Publications (1)

Publication Number Publication Date
PL3898637T3 true PL3898637T3 (pl) 2025-05-19

Family

ID=69165426

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19836546.2T PL3898637T3 (pl) 2018-12-18 2019-12-17 Pochodne rapamycyny

Country Status (20)

Country Link
US (1) US12281125B2 (pl)
EP (1) EP3898637B1 (pl)
JP (1) JP7618553B2 (pl)
KR (1) KR20210105397A (pl)
CN (1) CN113260619B (pl)
AU (1) AU2019409366B2 (pl)
BR (1) BR112021011325A2 (pl)
CA (1) CA3122922A1 (pl)
DK (1) DK3898637T3 (pl)
ES (1) ES3014225T3 (pl)
FI (1) FI3898637T3 (pl)
HR (1) HRP20250197T1 (pl)
HU (1) HUE070859T2 (pl)
LT (1) LT3898637T (pl)
MX (1) MX2021007247A (pl)
PL (1) PL3898637T3 (pl)
PT (1) PT3898637T (pl)
RS (1) RS66527B1 (pl)
SI (1) SI3898637T1 (pl)
WO (1) WO2020128861A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
BR112020025283A2 (pt) 2018-06-15 2021-03-09 Navitor Pharmaceuticals, Inc. Análogos de rapamicina e usos dos mesmos
EA202191983A1 (ru) 2019-01-22 2021-12-01 Аеовиан Фармасьютикалз, Инк. МОДУЛЯТОРЫ mTORC И ИХ ПРИМЕНЕНИЕ
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
IL296828A (en) 2020-03-27 2022-11-01 Aeovian Pharmaceuticals Inc mtorc1 modulators and their uses
WO2024211738A1 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Selective rapamycin analogs and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
CA2219080A1 (en) * 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamycin-based regulation of biological events
JP2002514893A (ja) 1995-06-07 2002-05-21 アリアド・ジーン・セラピューティクス・インコーポレイテッド 生物学的事象のラパマイシンに基づく調節
KR100400620B1 (ko) 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
CA2257803C (en) 1996-07-12 2008-12-02 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
AU755784B2 (en) 1998-01-15 2002-12-19 Ariad Pharmaceuticals, Inc. Regulation of biological events using multimeric chimeric proteins
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
EP3342411B1 (en) 2001-02-19 2019-08-21 Novartis Pharma AG Rapamycin derivative for treating pancreas cancer
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
GB0601406D0 (en) 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
US20090023768A1 (en) 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
RU2010104916A (ru) 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
US8906374B2 (en) 2010-04-20 2014-12-09 Cedars-Sinai Medical Center Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
WO2012103959A1 (en) 2011-02-04 2012-08-09 Synthon Bv Process for making everolimus
WO2012110953A1 (en) 2011-02-16 2012-08-23 Novartis Ag Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
EP3109250A1 (en) 2015-06-23 2016-12-28 Synbias Pharma AG Method for the synthesis of rapamycin derivatives
WO2017044720A1 (en) * 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
IL303660A (en) * 2017-05-02 2023-08-01 Revolution Medicines Inc Rapamycin analogs as mtor inhibitors
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
EP3947392B1 (en) 2019-03-26 2024-02-28 Novartis AG Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof

Also Published As

Publication number Publication date
SI3898637T1 (sl) 2025-04-30
AU2019409366A1 (en) 2021-06-10
ES3014225T3 (en) 2025-04-21
RS66527B1 (sr) 2025-03-31
KR20210105397A (ko) 2021-08-26
EP3898637A1 (en) 2021-10-27
PT3898637T (pt) 2025-02-24
EP3898637B1 (en) 2024-11-20
CN113260619B (zh) 2026-02-03
CN113260619A (zh) 2021-08-13
DK3898637T3 (da) 2025-02-17
WO2020128861A1 (en) 2020-06-25
AU2019409366B2 (en) 2022-10-27
MX2021007247A (es) 2021-07-15
HRP20250197T1 (hr) 2025-04-11
JP2022514254A (ja) 2022-02-10
BR112021011325A2 (pt) 2021-11-16
US20220064185A1 (en) 2022-03-03
JP7618553B2 (ja) 2025-01-21
US12281125B2 (en) 2025-04-22
FI3898637T3 (fi) 2025-02-24
LT3898637T (lt) 2025-03-10
CA3122922A1 (en) 2020-06-25
HUE070859T2 (hu) 2025-07-28

Similar Documents

Publication Publication Date Title
PT3958977T (pt) Derivados de camptotecina
PT3687999T (pt) Derivados de rapamicina
DK4073065T3 (da) Hidtil ukendte methylquinazolinonderivativer
EP3555124C0 (en) TCR NYESO
LT3810602T (lt) Junginiai
PL3897842T3 (pl) Pochodne bicykliczne
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
LT3830085T (lt) Deuterinti lanifibranoro dariniai
EP4013751C0 (en) 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES
DK3768669T3 (da) Piperazinazaspiroderivater
PL3898637T3 (pl) Pochodne rapamycyny
EP4077334C0 (en) FUROINDAZOLE DERIVATIVES
PT3625224T (pt) Derivados de indol n-substituídos
EP4021904C0 (en) ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
EP3885347A4 (en) DIHYDROPYRROLOPYRAZOLE DERIVATIVE
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
HUE065134T2 (hu) Vegyületek
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
EP3745904C0 (de) Stockgriff
EP3721129A4 (en) CRYOSPHERE
PT3796975T (pt) Derivados de sulfonilaminobenzamida
DK3645513T3 (da) Benzazepinderivater
DK3894410T3 (da) Substituerede xanthinderivater
EP3902806C0 (en) THIENOPYRIDINONE COMPOUNDS